Hi, help us enhance your experience
Hi, help us enhance your experience
Hi, help us enhance your experience
804 Views
eMediNexus 09 December 2017
The American Diabetes Associations annual guidelines for 2018 include novel recommendations for use of glucose-lowering drugs with proven cardiovascular benefit in type 2 diabetes, optimization of diabetes care in elderly patients, and glucose screening of high-risk adolescents. The most impactful new recommendation necessitates the use of a glucose-lowering agent with proven cardiovascular benefit, such as the glucagonlike peptide 1 (GLP-1) agonist liraglutide, and/or mortality reduction, such as that observed with the sodium glucose cotransporter-2 (SGLT2) inhibitor empagliflozin, in type 2 diabetes patients with established atherosclerotic cardiovascular disease (ASCVD) who fail to achieve glycemic targets with lifestyle modification and metformin. The ADA 2018 Standards of Medical Care in Diabetes are published online December 8, 2017 in Diabetes Care.
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}
{{Article_Author}}
{{Article_Title}}..
Detecting Intra-abdominal Adhesions in Women with Repeated C-sections..
Maintaining Liver Health to Optimize Glycemic Outcomes in Early Type 2.....
Antibiotic Prescribing Practices for Pediatric Acute Otitis Media..
Hidden Hazard of Indoor Pollution in COPD..
Recognizing Pitfalls of Point-of-Care Lung Ultrasound..
{{Article_Title}}..
Bombay HC Questions Denial of Motherhood to Woman with Intellectual Disability..
HMPV Outbreak in India: Health Minister Warns of Similar Symptoms to COVID-19, States Prepare Special ICU Wards..
Maharashtra Medical Education Minister Warns Children and Elderly to Stay Alert amid HMPV Cases..
Medical Negligence in Rewa: Surgical Needle Left inside Woman's Abdomen for Two Years..
HMPV in India: Seven Cases Reported across Four States..